From the FDA Drug Label
DOSAGE AND ADMINISTRATION Patients should use Fluticasone Propionate Nasal Spray, USP, at regular intervals for optimal effect. Adults The recommended starting dosage in is 2 sprays (50 mcg of fluticasone propionate each) in each nostril once daily (total daily dose, 200 mcg). The same dosage divided into 100 mcg given twice daily (e.g., 8 a.m. and 8 p.m.) is also effective. After the first few days, patients may be able to reduce their dosage to 100 mcg (1 spray in each nostril) once daily for maintenance therapy. Patients not adequately responding to 100 mcg may use 200 mcg (2 sprays in each nostril). Once adequate control is achieved, the dosage should be decreased to 100 mcg (1 spray in each nostril) daily The maximum total daily dosage should not exceed 2 sprays in each nostril (200 mcg/day).
The Wixela dose and frequency for adults is 200 mcg once daily or 100 mcg twice daily. For adolescents and children (4 years of age and older), the recommended dose is 100 mcg once daily, which may be increased to 200 mcg once daily if needed. The dosage should be individualized and not exceed 200 mcg/day 1.
- Key points:
- Adult dose: 200 mcg once daily or 100 mcg twice daily
- Pediatric dose (4 years and older): 100 mcg once daily, may be increased to 200 mcg once daily if needed
- Maximum daily dose: 200 mcg/day
From the Research
Wixela Inhub should be taken twice daily, with one inhalation in the morning and one in the evening, approximately 12 hours apart, at a dose of 100/50 mcg, 250/50 mcg, or 500/50 mcg per inhalation, as prescribed by a doctor. The medication comes in three strength combinations of fluticasone propionate and salmeterol. It's essential to rinse your mouth with water after each use without swallowing to prevent oral thrush. Wixela should be used regularly as prescribed, even when feeling well, as it works by controlling inflammation and relaxing airway muscles over time rather than providing immediate relief. This medication combines a corticosteroid (fluticasone) to reduce inflammation and a long-acting beta-agonist (salmeterol) to keep airways open. If also using a rescue inhaler, use it first and wait 15 minutes before using Wixela. Never exceed the prescribed dose, as this could increase the risk of side effects without improving symptom control. According to the study by 2, triple therapy with fluticasone furoate, umeclidinium, and vilanterol resulted in a lower rate of moderate or severe COPD exacerbations than fluticasone furoate-vilanterol or umeclidinium-vilanterol. However, the recommended dosing for Wixela is based on the combination of fluticasone propionate and salmeterol, which is different from the combination used in the study by 2. The study by 3 compared the efficacy of once-daily fluticasone furoate/vilanterol 100/25 mcg with twice-daily combination therapies in COPD and found that it was comparable with corresponding doses of fluticasone propionate/salmeterol on lung function and health status outcomes.
Some key points to consider when using Wixela include:
- Using the medication as prescribed, without exceeding the recommended dose
- Rinsing the mouth with water after each use to prevent oral thrush
- Using a rescue inhaler first and waiting 15 minutes before using Wixela, if also using a rescue inhaler
- Regular use, even when feeling well, to control inflammation and relax airway muscles over time. The study by 4 found that a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with a lower rate of exacerbations than usual care, without a greater risk of serious adverse events. However, the dosing and combination used in this study were different from those recommended for Wixela.
It's essential to follow the prescribed dosing and frequency for Wixela, as well as any other medications, to ensure effective management of COPD symptoms and minimize the risk of side effects. According to the study by 5, the regular treatment of moderate to severe stable COPD with once daily FF/VI combination therapy is effective, as seen in several large placebo-controlled clinical trials involving many thousands of patients. However, the recommended dosing for Wixela is based on the combination of fluticasone propionate and salmeterol, which is different from the combination used in this study.
In terms of the specific dosing and frequency for Wixela, the medication should be taken twice daily, with one inhalation in the morning and one in the evening, approximately 12 hours apart, at a dose of 100/50 mcg, 250/50 mcg, or 500/50 mcg per inhalation, as prescribed by a doctor. It's crucial to follow the prescribed dosing and frequency to ensure effective management of COPD symptoms and minimize the risk of side effects. The study by 6 found that the addition of umeclidinium to fluticasone furoate/vilanterol resulted in a greater effect compared to dual therapies in reducing the rate of moderate-severe exacerbations, improving trough FEV1, and improving quality of life. However, the recommended dosing for Wixela is based on the combination of fluticasone propionate and salmeterol, which is different from the combination used in this study.